NCT07432347 Decoding Epigenetic Mechanisms Driving Immune Evasion in Liver Cancer With Omics Approaches
| NCT ID | NCT07432347 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Niguarda Hospital |
| Condition | Hepatocarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 270 participants |
| Start Date | 2026-01-01 |
| Primary Completion | 2029-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 270 participants in total. It began in 2026-01-01 with a primary completion date of 2029-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a national, observational, retrospective, cross-sectional, non-profit study focused on patients with HCC. The study aims to characterize the expression and function of novel noncoding regulatory transcripts, including those containing TEsin the microenvironment of liver tumors, with emphasis on their role in T cell dysfunction.
Eligibility Criteria
1. Histological/radiological (LR-4 o 5)diagnosis of hepatocellular carcinoma (HCC). 2. Solid tumor fresh tissue availability from HCC biospy or surgical resectionas per standard clinical practice, and/orHCC FFPE archival samples availability. 3. Capability of understanding and signing an inform consent form. 4. Known hepatits B and C status, including HBeAg (positive or negative), viral load (HBVDNA e HCV-RNA), HCV genotype, whether sustained virological response (SVR)was obtainedand potential antiviral treatments received (including direct antiretroviral therapy(DAA)and interferon). These parameters will be exploited to stratify patients and analyze the impact of the virological status on microenvironmental immunological features, with particular regards to immunesuppression mechanisms.
Contact & Investigator
Gianluca Mauri, MD
PRINCIPAL INVESTIGATOR
ASST Grande Ospedale Metropolitano Niguarda
Frequently Asked Questions
Who can join the NCT07432347 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07432347 currently recruiting?
Yes, NCT07432347 is actively recruiting participants. Contact the research team at gianluca.mauri@ospedaleniguarda.it for enrollment information.
Where is the NCT07432347 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT07432347 clinical trial?
NCT07432347 is sponsored by Niguarda Hospital. The principal investigator is Gianluca Mauri, MD at ASST Grande Ospedale Metropolitano Niguarda. The trial plans to enroll 270 participants.